IDH1 and acute myeloid leukemia: FMS-like tyrosine kinase 3 (FLT3) inhibitors and Isocitrate dehydrogenase (IDH) inhibitors have been successfully employed in AML, inducing complete responses in a significant proportion of patients both as monotherapy and as a part of combination regimens.